October 15 | 2019
2cureX fortsätter sin IP-expansion genom säkrande av patent på sitt IndiTreat-test i Hong Kong
Read more
October 15 | 2019
2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong
Read more
October 8 | 2019
2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries
Read more
October 8 | 2019
2cureX har ingått avtal med ett av de största privata cancersjukhusen i Norden
Read more
September 25 | 2019
2cureX Newsletter September 2019
Read more
September 25 | 2019
2cureX Newsletter September 2019
Read more
August 23 | 2019
2cureX publishes half-year report for the first half of 2019
Read more
August 23 | 2019
2cureX offentliggör halvårsrapport för det första halvåret 2019
Read more
July 23 | 2019
2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial
Read more
July 23 | 2019
2cureX meddelar att patienter framgångsrikt inkluderats i pankreascancerstudie med IndiTreat®
Read more
June 27 | 2019
Last day of trading in BTA 1 in 2cureX AB
Read more
June 27 | 2019
Sista dag för handel med BTA 1 i 2cureX AB
Read more
June 25 | 2019
Byte av Certified Adviser till Svensk Kapitalmarknadsgranskning AB
Read more
June 25 | 2019
Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB
Read more
June 20 | 2019
2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer
Read more
June 20 | 2019
2cureX utser Dr. Henrik Harling till Chief Medical Officer
Read more
May 28 | 2019
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2019
Kommuniké från årsstämma i 2cureX AB (publ)
Read more